{"title":"抗凝剂更新II:新型口服抗凝剂","authors":"M.C. Montero Balosa , R.M. Moya Rodríguez","doi":"10.1016/S2172-3761(12)70062-6","DOIUrl":null,"url":null,"abstract":"<div><p>It shows a review of the new oral anticoagulants (dabigatran, rivaroxaban and apixaban). The paper evaluates the efficacy, safety and effectiveness of these drugs, including comparatively, and in relation to the classical K antagonists anticoagulants (warfarin and acenocumarol). Establishing the place of new oral anticoagulants in therapy based on patient characteristics and taking into account the risks and benefits associated with these new treatments, which have yet to be fully informed of its safety profile.</p></div>","PeriodicalId":100520,"journal":{"name":"Farmacéuticos de Atención Primaria","volume":"10 3","pages":"Pages 68-74"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2172-3761(12)70062-6","citationCount":"0","resultStr":"{\"title\":\"Actualización en anticoagulantes II: nuevos anticoagulantes orales\",\"authors\":\"M.C. Montero Balosa , R.M. Moya Rodríguez\",\"doi\":\"10.1016/S2172-3761(12)70062-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>It shows a review of the new oral anticoagulants (dabigatran, rivaroxaban and apixaban). The paper evaluates the efficacy, safety and effectiveness of these drugs, including comparatively, and in relation to the classical K antagonists anticoagulants (warfarin and acenocumarol). Establishing the place of new oral anticoagulants in therapy based on patient characteristics and taking into account the risks and benefits associated with these new treatments, which have yet to be fully informed of its safety profile.</p></div>\",\"PeriodicalId\":100520,\"journal\":{\"name\":\"Farmacéuticos de Atención Primaria\",\"volume\":\"10 3\",\"pages\":\"Pages 68-74\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S2172-3761(12)70062-6\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Farmacéuticos de Atención Primaria\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2172376112700626\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacéuticos de Atención Primaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2172376112700626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Actualización en anticoagulantes II: nuevos anticoagulantes orales
It shows a review of the new oral anticoagulants (dabigatran, rivaroxaban and apixaban). The paper evaluates the efficacy, safety and effectiveness of these drugs, including comparatively, and in relation to the classical K antagonists anticoagulants (warfarin and acenocumarol). Establishing the place of new oral anticoagulants in therapy based on patient characteristics and taking into account the risks and benefits associated with these new treatments, which have yet to be fully informed of its safety profile.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
